Fair Value of Financial Instruments - Schedule of Inputs and Valuation Methodologies Used (Details)	Jun. 30, 2024 USD ($)	Dec. 31, 2023 Y USD ($)
Fair Value of Financial Instruments
Debt Instrument, Valuation Technique [Extensible Enumeration]	us-gaap:ValuationTechniqueDiscountedCashFlowMember	us-gaap:ValuationTechniqueDiscountedCashFlowMember
Elusys Therapeutics | Maturity term | Convertible promissory note, related party
Fair Value of Financial Instruments
Convertible & Non-convertible promissory note, related party	1.2
Elusys Therapeutics | Market interest rate | Convertible promissory note, related party
Fair Value of Financial Instruments
Convertible & Non-convertible promissory note, related party	0.148
Elusys Therapeutics | Principal amount | Convertible promissory note, related party
Fair Value of Financial Instruments
Convertible & Non-convertible promissory note, related party	2,250,000
Convertible promissory note, related party | Elusys Therapeutics | Market interest rate | Non-convertible promissory note, related party
Fair Value of Financial Instruments
Convertible & Non-convertible promissory note, related party	15.3
Non-convertible promissory note, related party | Elusys Therapeutics | Maturity term
Fair Value of Financial Instruments
Convertible & Non-convertible promissory note, related party	1
Non-convertible promissory note, related party | Elusys Therapeutics | Principal amount
Fair Value of Financial Instruments
Convertible & Non-convertible promissory note, related party	800,000
Level 3 | Contingent consideration receivable, related party | Elusys Therapeutics | Maturity term
Fair Value of Financial Instruments
Contingent Consideration | Y		1
Level 3 | Contingent consideration receivable, related party | Elusys Therapeutics | Market interest rate
Fair Value of Financial Instruments
Contingent Consideration		0.147
Level 3 | Contingent consideration receivable, related party | Elusys Therapeutics | Principal amount
Fair Value of Financial Instruments
Contingent Consideration		2,250,000
Level 3 | Contingent earn-out receivable, related party | Elusys Therapeutics | Discount rate
Fair Value of Financial Instruments
Contingent Consideration	0.150	0.150
Level 3 | Contingent earn-out receivable, related party | Elusys Therapeutics | Future revenue projections
Fair Value of Financial Instruments
Contingent Consideration	153,200,000	141,400,000
Level 3 | Contingent earn-out receivable, related party | Elusys Therapeutics | Minimum earn-out payment rate
Fair Value of Financial Instruments
Contingent Consideration	3	0.03
Level 3 | Contingent earn-out receivable, related party | Elusys Therapeutics | Minimum earn-out payment
Fair Value of Financial Instruments
Contingent Consideration	5,000,000	5,000,000.0